Detailed Results of the LITESPARK-012 Trial Failure

Merck & Co., Inc. (MRK) and Eisai Co., Ltd. announced that their jointly developed hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, Welireg (belzutifan), failed to achieve the primary endpoints in the LITESPARK-012 Phase 3 clinical trial, which evaluated it as a first-line treatment. The trial involved patients with newly diagnosed, advanced clear cell Renal Cell Carcinoma (ccRCC) and compared a triple therapy regimen of Welireg, the immune checkpoint inhibitor Keytruda (pembrolizumab), and the tyrosine kinase inhibitor (TKI) Lenvima (lenvatinib) against the standard of care (SoC) of Keytruda and Lenvima as a doublet therapy. However, the trial did not demonstrate statistically significant improvements in progression-free survival (PFS) or overall survival (OS). Another treatment regimen evaluated in the trial, an immune-modulating triple therapy, also failed to demonstrate efficacy compared to the control group.

Merck's Post-Keytruda Strategy and Financial Impact

This clinical trial failure has a significant negative impact on Merck's medium- to long-term revenue diversification roadmap. Merck, which generates over $25 billion annually from its blockbuster immune checkpoint inhibitor Keytruda, had been aiming for Welireg's entry into the first-line kidney cancer market as a key growth driver to offset the 2028 expiration of Keytruda's U.S. patent. Market analysts had estimated that if Welireg had succeeded in this trial, the potential global annual revenue could have increased from the current forecast of $2.2 billion to as much as $5.8 billion due to the increase in long-term treatment patients. This additional growth potential has now been completely eliminated. On the day the news was released, Merck's stock price fell by approximately 4% on the New York Stock Exchange, reflecting the market's immediate concerns.

Changes in the Competitive Landscape of the First-Line Kidney Cancer Market

Welireg's clinical trial failure has provided a significant opportunity for its competitor, Arcus Biosciences (ARCX), to gain a stronger foothold in the market. Arcus is currently conducting the Phase 3 PEAK-1 clinical trial for patients with advanced clear cell Renal Cell Carcinoma, using casdatifan (AB521), a small molecule candidate that, like Welireg, inhibits the VHL/HIF-2α pathway. The previous ARC-20 trial demonstrated promising data with an objective response rate (ORR) of 45% and a median progression-free survival (mPFS) of 15.1 months in the 100mg monotherapy cohort. Arcus is expected to take an aggressive approach to capturing market share by capitalizing on the delay in Welireg's entry into the first-line treatment market.

Impact on Existing Approved Indications and Regulatory Outlook

However, this failure is not expected to have a direct impact on the sales of Welireg in other indications where it is already marketed and prescribed. Welireg received its first FDA approval in August 2021 for the treatment of tumors associated with von Hippel-Lindau (VHL) syndrome, and in December 2023, it received marketing approval for the treatment of recurrent advanced Renal Cell Carcinoma (RCC) after treatment with immune checkpoint inhibitors and VEGF-TKI, and is already experiencing strong growth. In fact, Welireg's global sales in 2025 are expected to increase by more than 40% year-over-year to $716 million, demonstrating its potential as a blockbuster drug. The FDA is currently reviewing an application for the approval of Welireg in combination with Lenvima for earlier lines of therapy.

Re-evaluation of the Peloton Acquisition Deal

Merck's May 2019 acquisition of Peloton Therapeutics is also being re-evaluated. At the time, Merck agreed to a total deal value of $2.2 billion, including an upfront payment of $1.05 billion and potential milestone payments of up to $1.15 billion, to acquire Welireg. While the company has begun to recoup a significant portion of the acquisition price through the approval of Welireg for second-line treatment and the VHL syndrome indication, the failure to achieve its ultimate goal of entering the first-line treatment market suggests that it may take some time to achieve the maximum return on investment (ROI) expected at the time of the acquisition.